Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.63 |
| ▸ | PARP1 | P09874 | 4/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CASP7 | P55210 | 2/20 | 0.47 |
| ▸ | RGS12 | O14924 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31241414 | 1.00 | CES1 (0.63) | CES1PARP1NPSR1MEN1KMT2A | |
| SCHEMBL6405656 | 0.92 | PARP1 (0.53) | CES1PARP1NPSR1MEN1KMT2A | |
| SCHEMBL5051981 | 0.84 | PARP1 (0.62) | CES1PARP1NPSR1MEN1KMT2A | |
| SCHEMBL14524815 | 0.83 | PARP1 (0.49) | CES1PARP1NPSR1MEN1KMT2A | |
| SCHEMBL14463494 | 0.79 | CASP1 (0.61) | CES1PARP1NPSR1MEN1KMT2A | |
| SCHEMBL8207983 | 0.78 | PARP1 (0.50) | CES1PARP1NPSR1MEN1KMT2A | |
| SCHEMBL2156357 | 0.77 | CES1 (1.00) | CES1NPSR1MEN1KMT2ACYP1A2 | |
| SCHEMBL579274 | 0.77 | CES1 (1.00) | CES1NPSR1MEN1KMT2ACYP1A2 | |
| SCHEMBL1654813 | 0.77 | ALOX5 (0.51) | PARP1MEN1KMT2ARECQLTDP1 | |
| SCHEMBL14524814 | 0.76 | PARP1 (0.51) | CES1PARP1NPSR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1042315-B1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE CO CHEM PHARM FAB (DE) | 2004-04-14 | — | — | EP | claimed |
| EP-1042315-A1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | Klinge Pharma GmbH (DE) | 2000-10-11 | — | — | EP | claimed |
| WO-1999031087-A1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | claimed |
| US-10103384-B2 | Electroactive polymers, manufacturing process thereof, electrode and use thereof | EVONIK DEGUSSA GMBH (DE) | 2018-10-16 | — | — | US | disclosed |
| EP-3019541-B1 | ELECTROACTIVE POLYMERS, MANUFACTURING PROCESS THEREOF, ELECTRODE AND USE THEREOF | EVONIK DEGUSSA GMBH (DE) | 2018-09-19 | — | — | EP | disclosed |
| US-20160233509-A1 | ELECTROACTIVE POLYMERS, MANUFACTURING PROCESS THEREOF, ELECTRODE AND USE THEREOF | EVONIK DEGUSSA GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
| EP-3019541-A1 | ELECTROACTIVE POLYMERS, MANUFACTURING PROCESS THEREOF, ELECTRODE AND USE THEREOF | Evonik Degussa GmbH (DE) | 2016-05-18 | — | — | EP | disclosed |
| US-20160067241-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | BROWN DENNIS M (US) | 2016-03-10 | — | — | US | disclosed |
| WO-2016028225-A1 | PLATINUM COMPLEXES AS ANTICANCER AGENTS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2016-02-25 | — | — | WO | disclosed |
| WO-2015003725-A1 | ELECTROACTIVE POLYMERS, MANUFACTURING PROCESS THEREOF, ELECTRODE AND USE THEREOF | FRIEDRICH-SCHILLER-UNIVERSITÄT JENA (DE) | 2015-01-15 | — | — | WO | disclosed |
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-09-09 | — | — | US | disclosed |
| EP-1079832-B1 | USE OF VITAMIN PP COMPOUNDS | KLINGE CO CHEM PHARM FAB (DE) | 2005-11-30 | — | — | EP | disclosed |
| EP-1042315-B1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE CO CHEM PHARM FAB (DE) | 2004-04-14 | — | — | EP | disclosed |
| EP-1079832-A1 | USE OF VITAMIN PP COMPOUNDS | Klinge Pharma GmbH (DE) | 2001-03-07 | — | — | EP | disclosed |
| EP-1042315-A1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | Klinge Pharma GmbH (DE) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999053920-A1 | USE OF VITAMIN PP COMPOUNDS | KLINGE PHARMA GMBH (DE) | 1999-10-28 | — | — | WO | disclosed |
| WO-1999031087-A1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | disclosed |
| EP-0536208-B1 | 1,2-DIHYDRO-3H-DIBENZISOQUINOLINE-1,3-DIONE ANTICANCER AGENTS | RES CORP TECHNOLOGIES INC (US) | 1998-01-21 | — | — | EP | disclosed |
| EP-0757676-A1 | DIHYDRODIBENZO(DE,H)ISOQUINOLINES DERIVATIVES AND THEIR USE AS ANTI-CANCER AGENTS | KNOLL AKTIENGESELLSCHAFT (DE) | 1997-02-12 | — | — | EP | disclosed |
| WO-1995029895-A1 | DIHYDRODIBENZO(DE,H)ISOQUINOLINES DERIVATIVES AND THEIR USE AS ANTI-CANCER AGENTS | KNOLL AKTIENGESELLSCHAFT (DE) | 1995-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067241-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | MYC, NME2, TP53 | CES1 300/4885PARP1 1586/4885NPSR1 3608/4885 |
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | PNPO, NAMPT, NAPRT | CES1 840/4885PARP1 255/4885NPSR1 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.